First FDA-Approved Study of Stem Cells to Treat Hearing Loss Begins at Children’s Memorial Hermann Hospital
HOUSTON, Jan. 12, 2012 /PRNewswire via COMTEX/ — Children’s Memorial Hermann Hospital and Cord Blood Registry® (CBR) are launching the first FDA-approved, Phase I safety study on the use of cord blood stem cells to treat children with sensorineural hearing loss.
To view the multimedia assets associated with this release, please visit: http://www.multivu.com/mnr/53686-cord-blood-childrens-memorial-hermann-fda-approved-stem-cells-hearing-loss
The study, which will use patients’ stem cells from their own stored umbilical cord blood, is the first of its kind, and has the potential to restore hearing. This follows evidence from published laboratory studies that cord blood helps repair damaged organs in the inner ear.
The year-long study will follow 10 children, ages 6 weeks to 18 months, who have sustained post-birth hearing loss. Children who are deaf as a result of a genetic anomaly or syndrome are not eligible. To ensure consistency in cord blood stem cell processing, storage, and release for infusion, CBR is the only stem cell bank providing clients for the study..